

RECEIVED
NOV 02 2001 CPA \$1619

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing

CHECK BOX, if applicable
☐ DUPLICATE

(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No. of Prior Application	09/446,328
	First Named Inventor	Ulrich SPECK et al.
	Examiner Name	M. Harley
	Group / Art Unit	1619
	Express Mail Label No.	23599

#11
11/28/01

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d),
(continued prosecution application (CPA)) of prior application number 09/446,328
filed on April 17, 2000, entitled USE OF INRAVENOUS CONTRAST MEDIA FOR PROJECTION MAMMOGRAPHY.

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

1. ☐ Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application
2. ☒ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4).
 - a. ☐ DELETE the following inventor(s) named in the prior nonprovisional application:

 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. ☐ Information Disclosure Statement (IDS) is enclosed:
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c) or (j))	28 -20* =	8	x \$18 =	\$ 144.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))	1 -3** =	3	x \$84 =	
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			x \$ =	
				BASIC FEE (37 CFR 1.16)	740.00
				Total of above Calculations =	884.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.27).				
	* Reissue claims in excess of 20 and over original patent.				
	** Reissue independent claims over original patent.				
	TOTAL =				884.00

6. ☐ Small entity status: Applicant claims small entity status. See 37 CFR 1.27.
7. ☐ The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. _____ - _____:
- a. ☐ Fees required under 37 CFR 1.16.
- b. ☐ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.
8. ☒ A check in the amount of \$ 884.00 and 920.00 is enclosed.
9. ☐ Payment by credit card. Form PTO-2038 is attached.
10. ☐ Applicant requests suspension of action under 37 CFR 1.103(b) (fee under 37 CFR 1.17(i) enclosed).
11. ☐ New Attorney Docket Number, if desired
[Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.]
12. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)
- b. ☒ Return Receipt Postcard (Should be specifically itemized, See MPEP 503)
13. ☐ Other: _____

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

12. NEW CORRESPONDENCE ADDRESS☒ Customer Number or Bar Code Labelor ☐ New correspondence address below

Name					
Address					
City		State		Zip Code	
Country		Telephone		Fax	

13. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print /Type)	Brian P. Heaney
Signature	
Registration No. (Attorney/Agent)	32,542
Date	October 30, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Ulrich SPECK et al.


Serial No.: 09/446,328

Filed: April 17, 2000

For: USE OF INTRAVENOUS CONTRAST MEDIA FOR PROJECTION MAMMOGRAPHY

Group Art Unit: 1619

Examiner: M. Harley



TECH CENTER 1600/2900

NOV 02 2001

RECEIVED

#12/B
HKD
11/28/01

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

In response to the Office Action of April 30, 2001, please amend the above-identified application as follows:

IN THE CLAIMS:

Please add the following new claims:

- B¹
- / 38. A method of projection mammography according to claim 19, wherein said intravenous contrast agent is a non-polymer iodine containing agent.
39. A method of projection mammography according to claim 19, wherein said intravenous contrast agent is a non-peptide iodine-containing agent.
40. A method of projection mammography according to claim 19, wherein said intravenous contrast agent is a monomeric non-ionic iodine-containing agent.
41. A method of projection mammography according to claim 19, wherein said intravenous contrast agent is a dimeric non-ionic iodine-containing agent.
42. A method of projection mammography according to claim 37, wherein said intravenous contrast agent is iopromide or iotrolan.
43. A method of projection mammography according to claim 21, wherein said intravenous contrast agent is N-cetyl-N,N,N-triethylammonium bromide.
44. A method of projection mammography according to claim 22, wherein said intravenous contrast agent contains a compound of an element of atomic number 83.

SCH-1653

*B¹
Contd*

45. A method of projection mammography according to claim 23, wherein said chelate is (4S)-4-(ethoxybenzyl)-3,6,9-tris(carboxymethyl)-3,6,9-triazaundecanoic acid. --
